In the teleconference they reported that over 70% of the sampled recordings (i.e. the ones they'd listened to) were audibly affected by background noise including televisions, conversations, medical equipment, other patients coughing, and even in some cases "coaching" coughs from parents or staff.
My understanding is that they investigated to the point where they were confident that they'd identified all the distinct causes of sound quality and didn't waste time beyond that.
Not all issues last year were related to data quality. There were also issues with the protocol. Asthma patients were treated already before they were tested by ResappDx. Given that Ventolin has almost immediate effect there was effectively nothing for ResappDx to detect. And finally as the comparison tests were adjudicated by different teams using different criteria there was no stable baseline for measuring results in some of the conditions.
- Forums
- ASX - By Stock
- RAP
- Ann: ResApp Provides SMARTCOUGH-C-2 Study Update
Ann: ResApp Provides SMARTCOUGH-C-2 Study Update, page-34
-
-
- There are more pages in this discussion • 36 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add RAP (ASX) to my watchlist
(20min delay)
|
|||||
Last
20.5¢ |
Change
0.000(0.00%) |
Mkt cap ! $176.2M |
Open | High | Low | Value | Volume |
0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Featured News
RAP (ASX) Chart |
Day chart unavailable